Phase 3Active, not recruiting

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Sponsor
Novartis Pharmaceuticals (Industry)
Enrollment
14,012 enrolled
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Placebo in 1.5ml
Ages
adults, older adults
Registry
NCT05739383

Full record on ClinicalTrials.gov

From the registry

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

Primary outcomes

  • Time to the first occurrence of 4P-MACE

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered